Platinum-Pemetrexed Chemotherapy for Recurrent Ovarian Cancer (ROC): A Single Center Experience.
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bevacizumab
/ administration & dosage
Carboplatin
/ administration & dosage
Female
Humans
Middle Aged
Neoplasm Recurrence, Local
/ drug therapy
Ovarian Neoplasms
/ drug therapy
Pemetrexed
/ administration & dosage
Retrospective Studies
Recurrent ovarian cancer
carboplatin
maintenance therapy
pemetrexed
platinum-sensitive ovarian cancer
Journal
Cancer investigation
ISSN: 1532-4192
Titre abrégé: Cancer Invest
Pays: England
ID NLM: 8307154
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
pubmed:
7
9
2021
medline:
30
10
2021
entrez:
6
9
2021
Statut:
ppublish
Résumé
In this retrospective analysis of 36 patients with recurrent ovarian cancer (ROC) treated with platinum pemetrexed doublet ± bevacizumab, the median age was 54.5 years (47-60) and 33 (91.7%) had serous histology. The overall response rate [ORR = complete (CR)+partial (PR) response] was 83.3%. At a median follow-up of 16 months, the median PFS was 13.8 months (95% CI: 10.849-20.580) and median OS 30.6 months, (95% CI: 21.46 months-NR). The incidence of Grade 3/4 anemia, thrombocytopenia, neutropenia and non-hematological toxicity was 19.4%, 3.9%, 16.6%, and 8.3%. Platinum pemetrexed chemotherapy in ROC is safe and effective treatment option.
Identifiants
pubmed: 34486892
doi: 10.1080/07357907.2021.1973021
doi:
Substances chimiques
Pemetrexed
04Q9AIZ7NO
Bevacizumab
2S9ZZM9Q9V
Carboplatin
BG3F62OND5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM